Levofloxacin Mesylate Sodium Chloride Injection

Levofloxacin mesylate.

This product is suitable for the following moderate and severe infections caused by sensitive bacteria: respiratory system infections: acute bronchitis, acute exacerbation of chronic bronchitis, diffuse bacterial bronchitis, bronchiectasis and infection, pneumonia, tonsillitis (peritonsillar abscess); urinary system infections: pyelonephritis, complicated urinary tract infection, etc.; reproductive system infections: acute prostatitis, acute epididymitis, uterine cavity infection, uterine adnexitis, pelvic inflammatory disease (metronidazole can be used in combination when anaerobic infection is suspected); skin and soft tissue infections: infectious impetigo, cellulitis, lymphangitis (adenitis), subcutaneous abscess, perianal abscess, etc.; intestinal infections: bacterial dysentery, infectious enteritis, salmonella

Intravenous drip: 400 mg per day for adults, divided into 2 intravenous drips. For patients with severe infections and those with pathogens that are less sensitive to this product (such as Pseudomonas aeruginosa), the maximum daily dose can be increased to 600 mg, divided into 2 intravenous drips.

During medication, symptoms such as nausea, vomiting, abdominal discomfort, diarrhea, loss of appetite, abdominal pain, and bloating may occur; neurological symptoms such as insomnia, dizziness, and headache; rash, itching, erythema, and redness and itching at the injection site or phlebitis may occur. Transient liver function abnormalities may also occur, such as increased blood transaminase and increased serum total bilirubin. The incidence of the above adverse reactions is between 0.1 and 5%. Occasionally, blood urea nitrogen rises, fatigue, fever, palpitations, abnormal taste, etc., which are generally tolerated and disappear quickly after the end of the course of treatment.

It is contraindicated for patients who are allergic to quinolones, pregnant or lactating women, and patients under 18 years of age.

Precautions for children: Not for use in patients under 18 years of age Precautions for pregnancy and lactation: Not for use in pregnant or lactating women. Precautions for the elderly: null

1. Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 2. When quinolone antibiotics are used in combination with theophylline, competitive inhibition of the cytochrome P450 binding site may lead to a significant reduction in the liver elimination of theophylline, a prolonged blood elimination half-life, an increase in blood drug concentration, and the appearance of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, agitation, convulsions, palpitations, etc. Although this product has little effect on the metabolism of theophylline, theophylline blood drug concentration should still be measured and the dosage adjusted when used in combination. 3. This product can increase the blood concentration of cyclosporine when used in combination with cyclosporine. The blood concentration of cyclosporine must be monitored and the dosage adjusted.

100ml: 0.5g levofloxacin mesylate (calculated as C18H20FN3O4) and 0.9g sodium chloride

China Resources Double-Crane Pharmaceutical Co., Ltd.

• Founded in:

  1997-05-16

• Address:

  No. 1, Lize East 2nd Road, Wangjing, Chaoyang District, Beijing

• Tax NO.:

  91110000633796475U

• Registered Funds:

  1,038,836,522 yuan

• Website:

  Log in to view

• Email:

  Log in to view